Cd-ISTAb is an engineered antibody for treatment of C. difficile infections (CDI). The strategy is based on a novel technology that uses Infection Site Targeted neutralizing anti-toxin Antibodies (ISTAb). ISTAbs are directed to the site of infection through specific phage-derived cell wall targeting (CWT) domains that bind specific bacterial species.
ISTABs unique properties:
- Accumulate at the site of infection through binding to the bacteria,
- Capturing and sequester the toxins as they are released, thereby immediately neutralizing their immune suppressive and tissue destructive effects and prevent toxemia.
- As the Fc receptor binding sites in the ISTAbs remain intact, ISTAbs mediate opsonophagocytic killing, thus providing a means for concurrent toxin neutralization and bacterial clearance.
Cd-ISTAb is a cocktail of two potent antibodies that neutralize C. difficile Toxin A (TcdA) and TcdB) and are targeted to the surface of bacteria.
- Karauzum et al., Synthetic human monoclonal antibodies toward staphylococcal enterotoxin B (SEB) protective against toxic shock syndrome, J Biol Chem, 2012
- Sully et al., A tripartite cocktail of chimeric monoclonal antibodies passively protects mice against ricin, staphylococcal enterotoxin B and Clostridium perfringens epsilon toxin, Toxicon, 2014